A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors (NCT07181473)
A Phase I, First in Human (FIH), Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Preliminary Efficacy and Immunogenicity of TJ101 for Injection in Patients With Advanced/Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to evaluate whether TJ101, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced solid tumors. The main objectives of this study are : * To Determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE) of TJ101 * to show preliminary antitumor activity in patients with advanced solid tumors Participants will: * Receive intravenous (IV) infusions of TJ101 at escalating dose levels (during dose escalation) or at the selected expansion dose. * Undergo regular tumor imaging to assess response. * Provide blood samples for pharmacokinetics (PK) and biomarker analysis. * Be monitored for side effects and overall tolerability. This study is being conducted in adult patients with advanced or metastatic solid tumors who have exhausted standard treatment options
Who can join: Review the eligibility criteria below.
Location: Florida Cancer Specialists & Research Institute — Orlando, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- Florida Cancer Specialists & Research Institute — Orlando, Florida
- Sarah Cannon Research Institute (SCRI) — Nashville, Tennessee
- Oncology Consultants — Houston, Texas
- Henan Cancer Hospital — Zhengzhou, Henan
- Union Hospital of Tongji Medical College — Wuhan, Hubei
- Sir Run Run Shaw Hospital — Hangzhou, Zhejiang
- Shanghai East Hospital — Shanghai,
📞 Contact the Study Coordinator
Phone: (551) 427-2578
Email: martin.olivo@phrontlinebio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Cancer (NSCLC)
- GCC 2545- Improving Post-Radiotherapy Respiratory Function Through Sparing Serial and Parallel Components in the Lung — Baltimore, Maryland
- Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 — Detroit, Michigan
- Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer — Kingsport, Tennessee
- A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation. — Cincinnati, Ohio
- Engagement of Veterans With Lung Cancer — Palo Alto, California
Explore by condition: All Lung Cancer (NSCLC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.